Tin tức & Cập nhật

Subcutaneous (SC) semaglutide 2.4 mg QW is recently granted accelerated approval by the US FDA for treatment of metabolic dysfunction–associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis.

Drug treatment for attention deficit/hyperactivity disorder (ADHD) may reduce the first occurrence rates of suicidal behaviours, substance misuse, transport accidents, and criminality, but not accidental injuries, suggest the results of a target trial emulation.